<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Visible haematuria — DGRefHelp Drafts</title>
  <link rel="stylesheet" href="../assets/site.css" />
</head>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">
        <h1><a href="../index.html">DGRefHelp drafts</a> / Visible haematuria</h1>
        <div class="sub">Evidence summary (key statements + how they fit together) → DGRefHelp first draft (D&amp;G).</div>
      </div>
      <div class="badges">
        <div class="badge">Mode: quick</div>
        <div class="badge">Last updated: 2026‑02‑12</div>
      </div>
    </div>

    <div class="grid">
      <div class="card">
        <div class="card-hd">
          <div class="tabs" data-tabs>
            <button class="tab" role="tab" data-tab="evidence" aria-selected="true">Evidence</button>
            <button class="tab" role="tab" data-tab="draft" aria-selected="false">DGRefHelp draft</button>
            <button class="tab" role="tab" data-tab="refs" aria-selected="false">References</button>
          </div>
          <div class="copybar">
            <button class="btn" data-copy-target="#draftText">Copy draft</button>
            <button class="btn" data-copy-target="#evidenceText">Copy evidence</button>
          </div>
        </div>

        <div class="card-bd">
          <div class="panel active" role="tabpanel" data-panel="evidence">
            <div id="evidenceText" class="section">
              <h3>Evidence summary (triangulated)</h3>

              <div class="callout ok">
                <strong>Key decision points to build the page around</strong>
                <ul>
                  <li><strong>Do not ignore visible haematuria</strong> (even if it is painless, intermittent, or there are "benign" explanations such as anticoagulation).</li>
                  <li><strong>Suspected cancer pathway (urology):</strong> NICE NG12 — age <strong>≥45</strong> with <strong>unexplained visible haematuria</strong> (no UTI) OR <strong>visible haematuria that persists/recurs after successful UTI treatment</strong> → suspected cancer pathway referral (bladder/renal).</li>
                  <li><strong>UTI is a common masking problem</strong> (esp. older women): SRG emphasises urine culture for all haematuria and avoiding repeated UTI treatment without reassessment if haematuria persists.</li>
                </ul>
              </div>

              <h4>1) NICE NG12 (urological cancers — haematuria)</h4>
              <ul>
                <li><strong>Bladder cancer (suspected cancer pathway):</strong> refer if age <strong>45+</strong> with unexplained visible haematuria without UTI, or visible haematuria that persists/recurs after successful UTI treatment. Also refer if age <strong>60+</strong> with unexplained non‑visible haematuria plus dysuria or raised WCC.</li>
                <li><strong>Renal cancer (suspected cancer pathway):</strong> refer if age <strong>45+</strong> with unexplained visible haematuria without UTI, or visible haematuria that persists/recurs after successful UTI treatment.</li>
                <li><strong>Recurrent/persistent unexplained UTI (age 60+):</strong> consider non‑urgent referral for bladder cancer.</li>
                <li><strong>Prostate cancer overlap:</strong> NG12 says consider PSA + DRE in people with LUTS or erectile dysfunction or visible haematuria; refer on age‑threshold PSA or malignant-feeling prostate.</li>
              </ul>

              <h4>2) Scottish Referral Guidelines / Right Decisions (Bladder &amp; kidney cancer)</h4>
              <ul>
                <li><strong>Urine culture</strong> should be obtained if a person presents with haematuria (visible or non-visible).</li>
                <li><strong>Under 45</strong>: a single episode of visible haematuria (no UTI) does <em>not</em> meet USC criteria; consider imaging or alternative urology pathway depending on local guidance.</li>
                <li>Notes groups at risk of diagnostic delay (e.g., older women with UTIs; recurrent UTIs).</li>
                <li>Suggests seeking urology advice if recurrent haematuria after <strong>recent negative investigations</strong> (does not need USC).</li>
              </ul>

              <h4>3) Practical primary care synthesis (what changes actions)</h4>
              <ul>
                <li><strong>Always confirm haematuria is urinary</strong> (vaginal bleeding, rectal bleeding, beetroot/dyes; myoglobin/haemolysis) and document whether it is visible vs dipstick-only.</li>
                <li>For suspected UTI, treat based on symptoms + culture guidance, but <strong>recheck</strong> if visible haematuria persists or recurs after treatment.</li>
                <li>Visible haematuria with red flags (clot retention, inability to pass urine, unstable patient) needs urgent acute assessment, not routine referral pathways.</li>
              </ul>

              <div class="callout warn">
                <strong>Local agreement needed (drafting-site only)</strong>
                <ul>
                  <li>Confirm the exact <strong>SCI Gateway destination/service naming</strong> for suspected urological cancer referral (bladder/renal) and the local direct-to-USOC vs generic "Urology" route.</li>
                  <li>Confirm whether D&amp;G expects any <strong>pre-referral tests</strong> beyond urine culture (e.g., repeat MSU, U&amp;Es/eGFR, FBC, PSA in men with LUTS, urine ACR for suspected renal cause).</li>
                  <li>Confirm whether primary care should request any <strong>imaging</strong> (e.g., renal tract USS) before routine urology referral for &lt;45s / low-risk scenarios.</li>
                </ul>
              </div>

              <div class="small">This evidence summary is written for pathway design: it highlights only decision‑changing points and where local policy choices sit.</div>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="draft">

            <div class="callout" style="margin-bottom:12px">
              <strong>Copy/paste HTML for Right Decisions accordion sections</strong>
              <div class="small">Per your preference, these snippets contain section content only (no internal headings). Paste each into the matching accordion section.</div>
              <div style="height:10px"></div>
              <div class="copybar" style="justify-content:flex-start">
                <button class="btn" data-copy-target="#htmlBackground">Copy Background HTML</button>
                <button class="btn" data-copy-target="#htmlAssessment">Copy Assessment HTML</button>
                <button class="btn" data-copy-target="#htmlPCM">Copy Primary care mgmt HTML</button>
                <button class="btn" data-copy-target="#htmlRefer">Copy Who to refer HTML</button>
                <button class="btn" data-copy-target="#htmlNotRefer">Copy Who not to refer HTML</button>
                <button class="btn" data-copy-target="#htmlRefs">Copy References HTML</button>
              </div>

              <details style="margin-top:10px">
                <summary class="small" style="cursor:pointer">Show HTML snippets</summary>

                <h4 style="margin:12px 0 6px">Background (HTML)</h4>
                <pre id="htmlBackground">&lt;ul&gt;
  &lt;li&gt;Visible haematuria (blood seen in urine) is a &lt;strong&gt;urological red flag&lt;/strong&gt; until proven otherwise.&lt;/li&gt;
  &lt;li&gt;Do not attribute visible haematuria to anticoagulation alone.&lt;/li&gt;
  &lt;li&gt;Common differentials: UTI, stones, benign prostatic disease, (less commonly) glomerular/renal disease, and urological malignancy.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Assessment (primary care) (HTML)</h4>
                <pre id="htmlAssessment">&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Confirm it is urinary&lt;/strong&gt;: exclude vaginal bleeding, rectal bleeding, food dyes; ask about timing (start/end of stream), clots, pain.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Red flags / same-day assessment:&lt;/strong&gt;
    &lt;ul&gt;
      &lt;li&gt;Haemodynamic instability, sepsis features, uncontrolled pain.&lt;/li&gt;
      &lt;li&gt;Inability to pass urine / clot retention.&lt;/li&gt;
      &lt;li&gt;Single kidney / immunosuppression + systemic illness (use judgement).&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Symptoms that guide differentials:&lt;/strong&gt;
    &lt;ul&gt;
      &lt;li&gt;Dysuria/frequency/urgency → consider UTI (but still safety‑net haematuria).&lt;/li&gt;
      &lt;li&gt;Colicky flank pain → consider stone.&lt;/li&gt;
      &lt;li&gt;LUTS (hesitancy/nocturia/poor flow) in men → consider prostate/BPH; consider PSA + DRE per NG12.&lt;/li&gt;
      &lt;li&gt;Proteinuria, oedema, hypertension → consider glomerular/renal cause (may need renal pathway).&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Tests (baseline):&lt;/strong&gt;
    &lt;ul&gt;
      &lt;li&gt;Urine dip (document blood, protein, nitrites, leucocytes).&lt;/li&gt;
      &lt;li&gt;Send &lt;strong&gt;urine culture&lt;/strong&gt; for all haematuria (visible or non-visible).&lt;/li&gt;
      &lt;li&gt;If visible haematuria is ongoing/significant: consider FBC, U&amp;Es/eGFR (local preference).&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Primary care management (HTML)</h4>
                <pre id="htmlPCM">&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;If UTI likely&lt;/strong&gt;: treat per local antimicrobial guidance and send culture.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Safety‑net tightly:&lt;/strong&gt; visible haematuria that &lt;strong&gt;persists or recurs&lt;/strong&gt; after treatment counts towards suspected cancer referral criteria (age thresholds apply).&lt;/li&gt;
  &lt;li&gt;Advise to seek urgent help if unable to pass urine, worsening pain, fever/rigors, or heavy bleeding/clots.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Who to refer (HTML)</h4>
                <pre id="htmlRefer">&lt;p&gt;&lt;strong&gt;Suspected cancer pathway (urology)&lt;/strong&gt; (NICE NG12)&lt;/p&gt;
&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Age ≥45&lt;/strong&gt; AND either:&lt;/li&gt;
  &lt;li&gt;
    &lt;ul&gt;
      &lt;li&gt;&lt;strong&gt;Unexplained visible haematuria&lt;/strong&gt; without UTI, OR&lt;/li&gt;
      &lt;li&gt;Visible haematuria that &lt;strong&gt;persists or recurs&lt;/strong&gt; after successful treatment of UTI.&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Route (draft):&lt;/strong&gt; SCI Gateway → DGRI → Urology → Suspected cancer pathway (bladder/renal).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Other / non-USC referral or advice (local pathways)&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
  &lt;li&gt;Age &lt;45 with visible haematuria (no UTI): consider routine urology or imaging based on local guidance.&lt;/li&gt;
  &lt;li&gt;Recurrent haematuria after recent negative investigations: consider urology advice (does not usually need USC).&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Who not to refer (HTML)</h4>
                <pre id="htmlNotRefer">&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Do not delay referral&lt;/strong&gt; by repeatedly treating presumed UTI if visible haematuria persists or recurs.&lt;/li&gt;
  &lt;li&gt;If visible haematuria is clearly explained by a transient benign cause and resolves completely, manage case-by-case with safety‑netting (local guidance applies).&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">References (HTML)</h4>
                <pre id="htmlRefs">&lt;ol&gt;
  &lt;li&gt;NICE NG12: Suspected cancer — recommendations organised by site of cancer. Urological cancers: bladder (1.6.4) and renal (1.6.6) suspected cancer referral criteria for visible haematuria (age ≥45; persists/recurs after UTI treatment). https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer (retrieved 2026‑02‑12)&lt;/li&gt;
  &lt;li&gt;Scottish Referral Guidelines for Suspected Cancer (Right Decisions): Bladder and kidney cancer (notes on urine culture for haematuria; under‑45 visible haematuria not USC; diagnostic delay risk groups). https://www.rightdecisions.scot.nhs.uk/scottish-referral-guidelines-for-suspected-cancer/urological-cancers/bladder-and-kidney-cancer/ (retrieved 2026‑02‑12)&lt;/li&gt;
&lt;/ol&gt;</pre>
              </details>
            </div>

            <div id="draftText" class="section">
              <h3>Visible haematuria</h3>

              <h4>Background</h4>
              <ul>
                <li>Visible haematuria (blood seen in urine) is a <strong>urological red flag</strong> until proven otherwise.</li>
                <li>Do not attribute visible haematuria to anticoagulation alone.</li>
                <li>Common differentials: UTI, stones, benign prostatic disease, (less commonly) glomerular/renal disease, and urological malignancy.</li>
              </ul>

              <h4>Assessment (primary care) — collapsible</h4>
              <ul>
                <li><strong>Confirm it is urinary:</strong> exclude vaginal bleeding, rectal bleeding, food dyes; ask about timing (start/end of stream), clots, pain.</li>

                <li><strong>Red flags / same‑day assessment:</strong>
                  <ul>
                    <li>Haemodynamic instability, sepsis features, uncontrolled pain.</li>
                    <li>Inability to pass urine / clot retention.</li>
                    <li>Single kidney / immunosuppression + systemic illness (use judgement).</li>
                  </ul>
                </li>

                <li><strong>Symptoms that guide differentials:</strong>
                  <ul>
                    <li>Dysuria/frequency/urgency → consider UTI (but still safety‑net haematuria).</li>
                    <li>Colicky flank pain → consider stone.</li>
                    <li>LUTS (hesitancy/nocturia/poor flow) in men → consider prostate/BPH; consider PSA + DRE per NG12.</li>
                    <li>Proteinuria, oedema, hypertension → consider glomerular/renal cause (may need renal pathway).</li>
                  </ul>
                </li>

                <li><strong>Tests (baseline):</strong>
                  <ul>
                    <li>Urine dip (document blood, protein, nitrites, leucocytes).</li>
                    <li>Send <strong>urine culture</strong> for all haematuria (visible or non-visible).</li>
                    <li>If visible haematuria is ongoing/significant: consider FBC, U&amp;Es/eGFR (local preference).</li>
                  </ul>
                </li>
              </ul>

              <h4>Primary care management</h4>
              <ul>
                <li><strong>If UTI likely:</strong> treat per local antimicrobial guidance and send culture.</li>
                <li><strong>Safety‑net tightly:</strong> visible haematuria that <strong>persists or recurs</strong> after treatment counts towards suspected cancer referral criteria (age thresholds apply).</li>
                <li>Advise to seek urgent help if unable to pass urine, worsening pain, fever/rigors, or heavy bleeding/clots.</li>
              </ul>

              <h4>Who to refer</h4>
              <p class="small">Use the correct urgency and the correct service destination. If in doubt, treat visible haematuria as high significance and seek advice.</p>

              <h4>Suspected cancer pathway (urology)</h4>
              <ul>
                <li><strong>NICE NG12:</strong> refer using a suspected cancer pathway for bladder/renal cancer if age <strong>≥45</strong> and either:</li>
                <li>
                  <ul>
                    <li><strong>Unexplained visible haematuria</strong> without UTI, or</li>
                    <li>Visible haematuria that <strong>persists or recurs</strong> after successful treatment of UTI.</li>
                  </ul>
                </li>
                <li><strong>Route (draft):</strong> SCI Gateway → DGRI → Urology → Suspected cancer pathway (bladder/renal).</li>
              </ul>

              <h4>Other / non-USC referral or advice (local pathways)</h4>
              <ul>
                <li>Age <strong>&lt;45</strong> with visible haematuria (no UTI): consider routine urology or imaging based on local guidance.</li>
                <li>Recurrent haematuria after recent negative investigations: consider urology advice (does not usually need USC).</li>
              </ul>

              <h4>Who not to refer</h4>
              <ul>
                <li><strong>Do not delay referral</strong> by repeatedly treating presumed UTI if visible haematuria persists or recurs.</li>
                <li>If visible haematuria is clearly explained by a transient benign cause and resolves completely, manage case-by-case with safety‑netting (local guidance applies).</li>
              </ul>

              <h4>Local agreement needed (drafting-site only)</h4>
              <ul>
                <li><label><input type="checkbox" disabled /> Confirm the exact <strong>SCI Gateway destination/service naming</strong> for suspected urological cancer referral (bladder/renal) and the local direct-to-USOC vs generic urology route.</label></li>
                <li><label><input type="checkbox" disabled /> Confirm whether D&amp;G expects any <strong>pre-referral tests</strong> beyond urine culture (e.g., U&amp;Es/eGFR, FBC, PSA in men with LUTS, urine ACR if renal cause suspected).</label></li>
                <li><label><input type="checkbox" disabled /> Confirm whether primary care should request any <strong>imaging</strong> (e.g., renal tract USS) before routine urology referral for &lt;45s / low-risk scenarios.</label></li>
              </ul>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="refs">
            <div class="section">
              <h3>References (retrieved 2026‑02‑12)</h3>
              <ol>
                <li>NICE NG12: Suspected cancer — recommendations organised by site of cancer. Urological cancers: bladder (1.6.4) and renal (1.6.6) suspected cancer referral criteria for visible haematuria (age ≥45; persists/recurs after UTI treatment). <a href="https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer">nice.org.uk</a></li>
                <li>Scottish Referral Guidelines for Suspected Cancer (Right Decisions): Bladder and kidney cancer (urine culture for haematuria; under‑45 visible haematuria not USC; diagnostic delay risk groups). <a href="https://www.rightdecisions.scot.nhs.uk/scottish-referral-guidelines-for-suspected-cancer/urological-cancers/bladder-and-kidney-cancer/">rightdecisions.scot.nhs.uk</a></li>
              </ol>
            </div>
          </div>

        </div>
      </div>

      <div class="footer">
        <a href="../index.html">← Back to topics</a>
      </div>
    </div>
  </div>

  <script src="../assets/site.js"></script>
</body>
</html>
